Park, Gun-Hoo
Noh, Haneul
Shao, Zhicheng http://orcid.org/0000-0001-9899-3730
Ni, Peiyan
Qin, Yiren
Liu, Dongxin
Beaudreault, Cameron P.
Park, Joy S.
Abani, Chiderah P. http://orcid.org/0000-0002-1718-5043
Park, James M.
Le, Derek T.
Gonzalez, Sasha Z.
Guan, Youxin http://orcid.org/0000-0003-0319-3621
Cohen, Bruce M.
McPhie, Donna L.
Coyle, Joseph T.
Lanz, Thomas A.
Xi, Hualin S.
Yin, Changhong
Huang, Weihua
Kim, Hae-Young http://orcid.org/0000-0001-7916-6625
Chung, Sangmi http://orcid.org/0000-0002-8737-9978
Funding for this research was provided by:
New York State Stem Cell Science (C32607GG, C32607GG)
U.S. Department of Health & Human Services | National Institutes of Health (MH107884)
Article History
Received: 1 August 2019
Accepted: 16 September 2020
First Online: 23 October 2020
Competing interests
: T.A.L. and H.S.X. were employees of Pfizer, Inc. at the time this work was performed. J.T.C. reports holding a patent on the use of <scp>d</scp>-serine to treat serious mental disorders that is owned by Massachusetts General Hospital and consulting with Concert Pharm.